SEC Tracker
Get the app

Oragenics OGEN

Oragenics FY 2021: net loss $15.7M

Form
10-K/A
Filed
Period
Importance
Routine
Document
10-K/A

Key figures from this report

These are the numbers Oragenics reported for the year ended Dec 31, 2021, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

  1. Net income−$15.7MAgainst −$26.4M in FY 202010-K/A income statement, on EDGAR
  2. Total deposits$18KNo year-earlier figure tagged10-K balance sheet, on EDGAR
  3. Stockholders’ equity$26.5M+57% from $16.8M in FY 202010-K/A balance sheet, on EDGAR

Every year in the financial tables

View on EDGAR

Open in the app

Get an email when Oragenics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. MetaVia MTVA public float $3M, Jun 30, 2025
  2. Inhibitor Therapeutics INTI public float $3M, Jun 30, 2025
  3. PTC Therapeutics PTCT public float $3M, Jun 30, 2025
  4. Integrated Biopharma INBP public float $3M, Dec 31, 2025
  5. Enveric Biosciences ENVB public float $4M, Jun 30, 2025